Collectively, these results suggest that FAK is involved in the tumorigenesis and progression of HNSCC and provides a therapeutic benefit to overcome tumor cell resistance to radiotherapy and chemotherapy. The gene discussed is PTK2; the disease is head and neck squamous cell carcinoma.